News | November 09, 2023
Bayer posts Q3 2023 Group sales Euro 10.34 billion
We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
The agreement demonstrates a shared commitment to advance precision medicine and improve patient outcomes in the region
KNISS has established a solid foundation of trust in the customers' minds, delivering high quality Products uncompromisingly.
US FDA approval is in line with de-risking strategy for additional API site to service our global customer base
Despite nearly 20 years of availability, biosimilars show worldwide adoption rate of only 14% in initiative-tracked countries, while reference medicines still represent 86% of biologic
The new Biolys provides higher concentration of L-lysine
The approval paves the way for consolidating the company’s position in Kenya and other African markets as part of its global expansion plans
The company moves a step closer towards achieving its goal of emerging as the top oncology medicine supplier from India in the ASEAN region
Company intends to increase sales in the UK to approximately 2 million Euros by focusing on seven molecules which are already registered in the country
Getinge has a strong market share in India within several product segments
Subscribe To Our Newsletter & Stay Updated
